RecruitingPhase 4NCT04119102

Duobrii in Combination With Biologics

Open Label Study Evaluating DUOBRII in Psoriasis Patients Being Treated With Biologic Agents.

Sponsor

Psoriasis Treatment Center of Central New Jersey

Enrollment

25 participants

Start Date

Oct 14, 2019

Study Type

INTERVENTIONAL

Conditions

12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeks

Min Age: 18 Years

Male or female adult ≥ 18 years of age;
Diagnosis of chronic plaque-type
Psoriasis affecting 2%-10% BSA
Patient is being treated with biologic therapy for a minimum of 24 weeks
Able and willing to give written informed consent prior to performance of any study-related procedures

Psoriasis affecting ˂2% or \>10% BSA
Patient not receiving a biologic agent, or receiving biologic agent \<24weeks
Received treatment with any topical antipsoriatic drug product within 14 days prior to the Baseline visit.
Has previously used DUOBRII

Interested in this trial?

Get notified about updates and connect with the research team.